Original Research

DOI: 10.4244/EIJ-D-24-00856

Prevalence, classification, and treatment of residual shunt after patent foramen ovale closure

Kristian Ujka1, MD; Alessandra Pizzuto1, MD; Mario Giordano2, MD; Francesca Maria Di Muro3, MD; Gianpiero Gaio2, MD; Maria Giovanna Russo2, MD; Berardo Sarubbi2, MD; Francesco Meucci3, MD; Giuseppe Santoro1, MD

Abstract

Background: Residual shunt (RS) after transcatheter patent foramen ovale (PFO) closure has been associated with an increased risk of recurrent stroke over long-term follow-up. However, RS prevalence, anatomical characteristics, and treatment strategies are poorly understood.

Aims: This study aimed to assess the prevalence and causes of RS, as well as to evaluate the safety and feasibility of its percutaneous treatment.

Methods: Patients with RS at transcranial Doppler after transcatheter PFO closure in three Italian high-volume centres between 2000 and 2022 were included. The prevalence and anatomical characteristics of RS, its relationship with the original occluding device, and the procedural details of percutaneous treatment were assessed.

Results: Among the 2,362 patients who underwent PFO closure, any grade and significant RS were diagnosed in 8.8% and 3.6% of patients, respectively. It was more frequently found after use of the NobleStitch system than after double-disc device implantation (20.0% vs 8.5%; p<0.00001). Among double-disc device implantations, a higher rate of shunt was found with stiffer devices (9.8% vs 7.1%; p<0.05) and with devices larger than 25 mm (13.9% vs 6.6%; p<0.00001). Intradiscal RS (type 1) was most common (43.6%), followed by extradiscal RS (type 2; 35.1%) and RS due to unusual causes (type 3; 14.9%). Percutaneous treatment was successful in 89.4% of patients using different, anatomically tailored devices.

Conclusions: RS is commonly found after transcatheter PFO closure and is significantly associated with the type and size of the occluding device implanted. It results from different mechanisms and can be safely and effectively treated by a percutaneous, patient-tailored approach in a high percentage of cases.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 16
Aug 18, 2025
Volume 21 Number 16
View full issue


Key metrics

Suggested by Cory

CLINICAL RESEARCH

10.4244/EIJ-D-17-00061 Sep 20, 2017
Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale
Susuri N et al
free

IMAGE IN CARDIOLOGY

10.4244/EIJV10I7A146 Nov 20, 2014
Percutaneous reclosure of a patent foramen ovale after bioabsorbable device implantation
Snijder R et al
free

Research correspondence

10.4244/EIJ-D-21-01021 May 15, 2022
Mechanisms of ineffective patent foramen ovale closure using the percutaneous suture-mediated NobleStitch system
Zannoni J et al
free

Editorial

10.4244/EIJ-E-25-00025 Aug 18, 2025
Does a positive bubble study after PFO closure matter: is it much ado about nothing or an indication for reintervention?
Horlick E and Abrahamyan L
free
Trending articles
96.55

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
66.9

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
56.6

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.6

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
35.45

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved